All Industries

Top Biopharmaceutical Companies

15 Biopharmaceutical companies, sorted by total funding raised.

ArcellxIPO

Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable...

Redwood City51–200Biopharmaceutical, Oncology
Seed·$375.0M·Jan 2024
ErytechClosed

A clinical-stage biopharma company based in Lyon, France

Lyon, France51–200Biopharmaceutical, Therapeutics
Private Equity·$274.6M·Nov 2017
Inventiva PharmaIPO

Clinical-stage biopharmaceutical company focused on the development of oral small molecule therap...

Daix, France51–200Biopharmaceutical, MASH Treatment
Growth Equity·$232.0M·May 2025
Centrexion Therapeutics

Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe...

Boston, United States11–50Biopharmaceutical, CNS
Venture Unknown·$192.4M·Jun 2023
Addex TherapeuticsIPO

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally ava...

Plan-les-Ouates, Switzerland11–50Biopharmaceutical, Biotech
Extension Round·$155.9M·Aug 2022
ArdelyxIPO

Focused on the discovery and development of novel therapeutics acting exclusively in the gastroin...

Fremont, United States201–500Biopharmaceutical, Therapeutics
Private Equity·$140.0M·Jul 2016
Cadence PharmaceuticalsClosed

Hospital-focused biopharmaceutical company

San Diego, United States51–200Biopharmaceutical, Hospital
Series A·$86.6M·Feb 2009
Adimab

Provides antibody discovery and engineering services to biopharma partners using a yeast-based pl...

Lebanon, United States51–200Antibody Discovery, Biopharmaceutical
Series F·$26.0M·Jan 2012
CerecorClosed

Clinical stage biopharmaceutical company focused on the development of drugs to treat diseases of...

Baltimore, United States11–50Biopharmaceutical, Biotech
Series A·$22.0M·Jan 2012
Akari TherapeuticsIPO

Biotechnology company developing advanced therapies for autoimmune and inflammatory diseases.

London, United Kingdom1–10Antibody-Drug Conjugates, Biopharmaceutical
Venture Unknown·$14.6M·Dec 2025
Annexon, Inc.

R&D company with 1 SBIR/STTR awards from Department of Health and Human Services.

South San Francisco, United States1–10Biotech, Healthcare
Funding undisclosed
VerastemIPO
Boston, United StatesBiopharmaceutical, healthtech
Funding undisclosed
Lumos Pharma

Developing a novel therapeutic for the rare disease Creatine Transporter Deficiency, an inborn er...

Austin, United States11–50Biopharmaceutical, Rare diseases
Series B·Apr 2016
ILC Dover

Portfolio company

Frederica, United StatesAerospace, Biopharmaceutical
Funding undisclosed
ComplexaClosed

Developing disease-modifying nitro fatty acid platform technology for patients with fibrosis and ...

Berwyn11–50Biopharmaceutical, Drug Development
Series C·Jul 2017